Dose escalation can maximize therapeutic potential of sunitinib in patients with metastatic renal cell carcinoma

Anikó Maráz, Adrienn Cserháti, Gabriella Uhercsák, Éva Szilágyi, Zoltán Varga, János Révész, Renáta Kószó, Linda Varga, Zsuzsanna Kahán

Research output: Article

2 Citations (Scopus)

Abstract

Background: In patients with metastatic renal cell cancer, based on limited evidence, increased sunitinib exposure is associated with better outcome. The survival and toxicity data of patients receiving individualized dose escalated sunitinib therapy as compared to standard management were analyzed in this study. Methods: From July 2013, the data of metastatic renal cell cancer patients with slight progression but still a stable disease according to RECIST 1.1 criteria treated with an escalated dose of sunitinib (first level: 62.5 mg/day in 4/2 or 2×2/1 scheme, second level: 75 mg/day in 4/2 or 2×2/1 scheme) were collected prospectively. Regarding characteristics, outcome, and toxicity data, an explorative retrospective analysis of the register was carried out, comparing treatments after and before July 1, 2013 in the study (selected patients for escalated dose) and control (standard dose) groups, respectively. Results: The study involved 103 patients receiving sunitinib therapy with a median overall and progression free survival of 25.36±2.62 and 14.2±3.22 months, respectively. Slight progression was detected in 48.5% of them. First and second-level dose escalation were indicated in 18.2% and 4.1% of patients, respectively. The dosing scheme was modified in 22.2%. The median progression free survival (39.7±5.1 vs 14.2±1.3 months (p=0.037)) and the overall survival (57.5±10.7 vs 27.9±2.5 months (p=0.044)) were significantly better in the study group (with dose escalation) than in the control group. Patients with nephrectomy and lower Memorial Sloan Kettering Cancer Center (MSKCC) scores showed more favorable outcomes. After dose escalation, the most common adverse events were worsening or development of fatigue, hypertension, stomatitis, and weight loss of over 10%. Conclusions: Escalation of sunitinib dosing in selected patients with metastatic renal cell cancer, especially in case of slight progression, based on tolerable toxicity is safe and improves outcome. Dose escalation in 12.5 mg steps may be recommended for properly educated patients.

Original languageEnglish
Article number296
JournalBMC Cancer
Volume18
Issue number1
DOIs
Publication statusPublished - márc. 15 2018

Fingerprint

Renal Cell Carcinoma
Therapeutics
Disease-Free Survival
sunitinib
Stomatitis
Survival
Nephrectomy
Fatigue
Weight Loss
Hypertension
Control Groups

ASJC Scopus subject areas

  • Oncology
  • Genetics
  • Cancer Research

Cite this

Dose escalation can maximize therapeutic potential of sunitinib in patients with metastatic renal cell carcinoma. / Maráz, Anikó; Cserháti, Adrienn; Uhercsák, Gabriella; Szilágyi, Éva; Varga, Zoltán; Révész, János; Kószó, Renáta; Varga, Linda; Kahán, Zsuzsanna.

In: BMC Cancer, Vol. 18, No. 1, 296, 15.03.2018.

Research output: Article

Maráz, A, Cserháti, A, Uhercsák, G, Szilágyi, É, Varga, Z, Révész, J, Kószó, R, Varga, L & Kahán, Z 2018, 'Dose escalation can maximize therapeutic potential of sunitinib in patients with metastatic renal cell carcinoma', BMC Cancer, vol. 18, no. 1, 296. https://doi.org/10.1186/s12885-018-4209-9
Maráz, Anikó ; Cserháti, Adrienn ; Uhercsák, Gabriella ; Szilágyi, Éva ; Varga, Zoltán ; Révész, János ; Kószó, Renáta ; Varga, Linda ; Kahán, Zsuzsanna. / Dose escalation can maximize therapeutic potential of sunitinib in patients with metastatic renal cell carcinoma. In: BMC Cancer. 2018 ; Vol. 18, No. 1.
@article{0fe9154934444e2391d1014cbbbbe2f5,
title = "Dose escalation can maximize therapeutic potential of sunitinib in patients with metastatic renal cell carcinoma",
abstract = "Background: In patients with metastatic renal cell cancer, based on limited evidence, increased sunitinib exposure is associated with better outcome. The survival and toxicity data of patients receiving individualized dose escalated sunitinib therapy as compared to standard management were analyzed in this study. Methods: From July 2013, the data of metastatic renal cell cancer patients with slight progression but still a stable disease according to RECIST 1.1 criteria treated with an escalated dose of sunitinib (first level: 62.5 mg/day in 4/2 or 2×2/1 scheme, second level: 75 mg/day in 4/2 or 2×2/1 scheme) were collected prospectively. Regarding characteristics, outcome, and toxicity data, an explorative retrospective analysis of the register was carried out, comparing treatments after and before July 1, 2013 in the study (selected patients for escalated dose) and control (standard dose) groups, respectively. Results: The study involved 103 patients receiving sunitinib therapy with a median overall and progression free survival of 25.36±2.62 and 14.2±3.22 months, respectively. Slight progression was detected in 48.5{\%} of them. First and second-level dose escalation were indicated in 18.2{\%} and 4.1{\%} of patients, respectively. The dosing scheme was modified in 22.2{\%}. The median progression free survival (39.7±5.1 vs 14.2±1.3 months (p=0.037)) and the overall survival (57.5±10.7 vs 27.9±2.5 months (p=0.044)) were significantly better in the study group (with dose escalation) than in the control group. Patients with nephrectomy and lower Memorial Sloan Kettering Cancer Center (MSKCC) scores showed more favorable outcomes. After dose escalation, the most common adverse events were worsening or development of fatigue, hypertension, stomatitis, and weight loss of over 10{\%}. Conclusions: Escalation of sunitinib dosing in selected patients with metastatic renal cell cancer, especially in case of slight progression, based on tolerable toxicity is safe and improves outcome. Dose escalation in 12.5 mg steps may be recommended for properly educated patients.",
keywords = "Dose escalation, Improved outcome, Metastatic renal cell cancer, Sunitinib, Toxicity",
author = "Anik{\'o} Mar{\'a}z and Adrienn Cserh{\'a}ti and Gabriella Uhercs{\'a}k and {\'E}va Szil{\'a}gyi and Zolt{\'a}n Varga and J{\'a}nos R{\'e}v{\'e}sz and Ren{\'a}ta K{\'o}sz{\'o} and Linda Varga and Zsuzsanna Kah{\'a}n",
year = "2018",
month = "3",
day = "15",
doi = "10.1186/s12885-018-4209-9",
language = "English",
volume = "18",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Dose escalation can maximize therapeutic potential of sunitinib in patients with metastatic renal cell carcinoma

AU - Maráz, Anikó

AU - Cserháti, Adrienn

AU - Uhercsák, Gabriella

AU - Szilágyi, Éva

AU - Varga, Zoltán

AU - Révész, János

AU - Kószó, Renáta

AU - Varga, Linda

AU - Kahán, Zsuzsanna

PY - 2018/3/15

Y1 - 2018/3/15

N2 - Background: In patients with metastatic renal cell cancer, based on limited evidence, increased sunitinib exposure is associated with better outcome. The survival and toxicity data of patients receiving individualized dose escalated sunitinib therapy as compared to standard management were analyzed in this study. Methods: From July 2013, the data of metastatic renal cell cancer patients with slight progression but still a stable disease according to RECIST 1.1 criteria treated with an escalated dose of sunitinib (first level: 62.5 mg/day in 4/2 or 2×2/1 scheme, second level: 75 mg/day in 4/2 or 2×2/1 scheme) were collected prospectively. Regarding characteristics, outcome, and toxicity data, an explorative retrospective analysis of the register was carried out, comparing treatments after and before July 1, 2013 in the study (selected patients for escalated dose) and control (standard dose) groups, respectively. Results: The study involved 103 patients receiving sunitinib therapy with a median overall and progression free survival of 25.36±2.62 and 14.2±3.22 months, respectively. Slight progression was detected in 48.5% of them. First and second-level dose escalation were indicated in 18.2% and 4.1% of patients, respectively. The dosing scheme was modified in 22.2%. The median progression free survival (39.7±5.1 vs 14.2±1.3 months (p=0.037)) and the overall survival (57.5±10.7 vs 27.9±2.5 months (p=0.044)) were significantly better in the study group (with dose escalation) than in the control group. Patients with nephrectomy and lower Memorial Sloan Kettering Cancer Center (MSKCC) scores showed more favorable outcomes. After dose escalation, the most common adverse events were worsening or development of fatigue, hypertension, stomatitis, and weight loss of over 10%. Conclusions: Escalation of sunitinib dosing in selected patients with metastatic renal cell cancer, especially in case of slight progression, based on tolerable toxicity is safe and improves outcome. Dose escalation in 12.5 mg steps may be recommended for properly educated patients.

AB - Background: In patients with metastatic renal cell cancer, based on limited evidence, increased sunitinib exposure is associated with better outcome. The survival and toxicity data of patients receiving individualized dose escalated sunitinib therapy as compared to standard management were analyzed in this study. Methods: From July 2013, the data of metastatic renal cell cancer patients with slight progression but still a stable disease according to RECIST 1.1 criteria treated with an escalated dose of sunitinib (first level: 62.5 mg/day in 4/2 or 2×2/1 scheme, second level: 75 mg/day in 4/2 or 2×2/1 scheme) were collected prospectively. Regarding characteristics, outcome, and toxicity data, an explorative retrospective analysis of the register was carried out, comparing treatments after and before July 1, 2013 in the study (selected patients for escalated dose) and control (standard dose) groups, respectively. Results: The study involved 103 patients receiving sunitinib therapy with a median overall and progression free survival of 25.36±2.62 and 14.2±3.22 months, respectively. Slight progression was detected in 48.5% of them. First and second-level dose escalation were indicated in 18.2% and 4.1% of patients, respectively. The dosing scheme was modified in 22.2%. The median progression free survival (39.7±5.1 vs 14.2±1.3 months (p=0.037)) and the overall survival (57.5±10.7 vs 27.9±2.5 months (p=0.044)) were significantly better in the study group (with dose escalation) than in the control group. Patients with nephrectomy and lower Memorial Sloan Kettering Cancer Center (MSKCC) scores showed more favorable outcomes. After dose escalation, the most common adverse events were worsening or development of fatigue, hypertension, stomatitis, and weight loss of over 10%. Conclusions: Escalation of sunitinib dosing in selected patients with metastatic renal cell cancer, especially in case of slight progression, based on tolerable toxicity is safe and improves outcome. Dose escalation in 12.5 mg steps may be recommended for properly educated patients.

KW - Dose escalation

KW - Improved outcome

KW - Metastatic renal cell cancer

KW - Sunitinib

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=85043793064&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043793064&partnerID=8YFLogxK

U2 - 10.1186/s12885-018-4209-9

DO - 10.1186/s12885-018-4209-9

M3 - Article

C2 - 29544452

AN - SCOPUS:85043793064

VL - 18

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

IS - 1

M1 - 296

ER -